Review of the most common methods applied for in-vitro research in non-small cell lung cancer from last decade
most common methods applied for in-vitro research in NSCLC
Ključne reči:
NSCLC, ćelijske linije raka pluća, EGFR, polimorfizmi, metode.
Sažetak
Uvod/Cilj. Receptor epidermalnog faktora rasta (EGFR) je jedan od ključnih tumorskih markera nesitnoćelijskog karcinoma pluća (NSCLC) i smernica za izbor terapijskih procedura. Cilj rada je da proceni metode korišćene u istraživanju EGFR varijanti na ćelijskim linijama NSCLC i kombinovanim istraživanjima (NSCLC ćelijske linije i uzorci dobijeni od pacijenata) u poslednjoj deceniji, u različitim geografskim oblastima.
Materijali i metode. Studija je obuhvatila 185 članaka u punom tekstu u kojima su mutacije EGFR ispitivane na NSCLC ćelijskim linijama i 37 članaka u punom tekstu koji su analizirali EGFR varijante u kombinovanim istraživanjima, objavljenim od 1. januara 2010. do aprila 2020. Deskriptivna statistika je urađena koristeći originalni softver Microsoft Excel 2007.
Rezultati. Dobijeni rezultati su pokazali da su western blot, MTT test citotoksičnosti i lančana reakcija polimeraze (PCR) najviše korišćene metode u proučavanju EGFR varijanti na NSCLC ćelijskim linijama. U kombinovanim istraživanjima EGFR varijanti, na ćelijskim linijama i uzorcima dobijenim od pacijenata, najčešće se koriste sekvenciranje, PCR i western blot. Najveći broj objavljenih radova obe grupe istraživanja objavljen je sa azijskog kontinenta.
Zaključak. Postoji razlika u pregledu najčešće korišćenih metoda u testiranju varijanti EGFR u istraživanjima na NSCLC ćelijskim linijama i u kombinovanim studijama. Zajednička karakteristika obe vrste istraživanja je da većina objavljenih članaka u punom tekstu o varijanti EGFR gena kod NSCLC potiču sa azijskog kontinenta u poslednjoj deceniji.
Reference
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021 [published correction appears in CA Cancer J Clin. 2021 Jul;71(4):359]. CA Cancer J Clin. 2021;71(1):7-33. https://doi.org/10.3322/caac.21654
2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1 Suppl):21S-49S. https://doi.org/10.1378/chest.123.1_suppl.21s
3. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5-8. https://doi.org/10.1164/ajrccm.161.1.9906062
4. Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45(1):103-110. https://doi.org/10.1086/518606
5. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17(3):362-387. https://doi.org/10.1016/j.jtho.2021.11.003
6. Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937-970. https://doi.org/10.1002/cac2.12359
7. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-1260. https://doi.org/10.1097/JTO.0000000000000630
8. Yatabe Y. Molecular pathology of non-small cell carcinoma. Histopathology. 2024;84(1):50-66. https://doi.org/10.1111/his.15080
9. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7(10):2958-2970.
10. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37 Suppl 4:S9-S15. https://doi.org/10.1016/s0959-8049(01)00231-3
11. Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35(4):575-588. https://doi.org/10.1007/s10555-016-9649-6
12. Verusingam ND, Chen YC, Lin HF, et al. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. J Chin Med Assoc. 2021;84(3):248-254. https://doi.org/10.1097/jcma.0000000000000438
13. Provenzano M, Mocellin S. Complementary techniques: validation of gene expression data by quantitative real time PCR. Adv Exp Med Biol. 2007;593:66-73. https://doi.org/10.1007/978-0-387-39978-2_7
14. Shen J, Behrens C, Wistuba II, et al. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006;66(23):11194-11206. https://doi.org/10.1158/0008-5472.CAN-04-1444
15. Liu J, Lee W, Jiang Z, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012;22(12):2315-2327. https://doi.org/10.1101/gr.140988.112
16. Okada S, Kobayashi S, Inaba H, et al. Flow cytometric DNA analysis of lung cancer cell lines. Tohoku J Exp Med. 1992;168(2):307-310. https://doi.org/10.1620/tjem.168.307
17. Neuperger P, Puskás GL, Szebeni JG. A humán H1975 tüdő- és MDA-MB-231 emlőadenokarcinóma-sejtes modellek egysejt-tömegcitometriás összehasonlító elemzése [Single cell mass cytometric comparison of human H1975 lung and MDA-MD-231 breast adenocarcinoma cellular models]. Magy Onkol. 2021;65(2):129-138.
18. Sakamoto Y, Xu L, Seki M, et al. Long-read sequencing for non-small-cell lung cancer genomes. Genome Res. 2020;30(9):1243-1257. https://doi.org/10.1101/gr.261941.120.
19. Mirabelli P, Coppola L, Salvatore M. Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers (Basel). 2019;11(8):1098. Published 2019 Aug 1. https://doi.org/10.3390/cancers11081098
20. Hynds RE, Frese KK, Pearce DR, Grönroos E, Dive C, Swanton C. Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biol. 2021;11(1):200247. https://doi.org/10.1098/rsob.200247
21. Tsai JR, Wang HM, Liu PL, et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell Oncol (Dordr). 2012;35(6):461-471. https://doi.org/10.1007/s13402-012-0105-5
22. Guernet A, Mungamuri SK, Cartier D, et al. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. Mol Cell. 2016;63(3):526-538. https://doi.org/10.1016/j.molcel.2016.06.017
23. Chang TH, Tsai MF, Su KY, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011;183(8):1071-1079. https://doi.org/10.1164/rccm.201009-1440OC
24. Obradovic J, Todosijevic J, Jurisic V. Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Mol Biol Rep. 2021;48(4):3593-3604. https://doi.org/10.1007/s11033-021-06379-w
25. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases [published correction appears in Nat Rev Cancer. 2015 Apr;15(4):247]. Nat Rev Cancer. 2014;14(8):535-546. https://doi.org/10.1038/nrc3775
26. Yablonskii, P., Nefedov, A., Arseniev, A., Kozak, A., Mortada, M., & Patsyuk, A. Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability? AME Medical Journal 5 (2020): 10-10. https://doi:10.21037/amj.2020.02.07
27. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637-658. https://doi.org/10.1038/nrc.2017.84
28. Padinharayil H, Varghese J, John MC, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 2022;10(3):960-989. Published 2022 Aug 23. https://doi.org/10.1016/j.gendis.2022.07.023
29. Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1(1):5-13. https://doi.org/10.3978/j.issn.2218-6751.2011.12.01
30. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019;94(8):1623-1640. https://doi.org/10.3978/j.issn.2218-6751.2011.12.01
31. Zhang Q, Li D, Liu Y, et al. Potential anticancer activity of curcumin analogs containing sulfone on human cancer cells. Archives of Biological Sciences. 2016;68(1):125-133. Accessed January 25, 2024. https://doiserbia.nb.rs/Article.aspx?id=0354-46641500134Z
32. Turkez, H., Arslan, M. E., & Ozdemir, O. Genotoxicity testing: progress and prospects for the next decade. Expert Opin Drug Metab Toxicol. 2017;1089–1098. https://doi.org/10.1080/17425255.2017.1375097
33. Jurisic V, Bogdanovic G, Kojic V, Jakimov D, Srdic T. Effect of TNF-alpha on Raji cells at different cellular levels estimated by various methods. Ann Hematol. 2006;85(2):86-94. https://doi.org/10.1007/s00277-005-0010-3
34. Vuletic A, Konjevic G, Milanovic D, Ruzdijic S, Jurisic V. Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells. Pathol Oncol Res. 2010;16(3):393-401. https://doi.org/10.1007/s12253-009-9241-2
35. Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M. TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239(3):115-122. https://doi.org/10.1007/s00232-010-9309-7
36. Rice SJ, Liu X, Wang HG, Belani CP. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer. PLoS One. 2019;14(5):e0217657. Published 2019 May 31. https://doi.org/10.1371/journal.pone.0217657
37. Maj E, Maj B, Bobak K, et al. Differential Response of Lung Cancer Cells, with Various Driver Mutations, to Plant Polyphenol Resveratrol and Vitamin D Active Metabolite PRI-2191. Int J Mol Sci. 2021;22(5):2354. Published 2021 Feb 26. doi:10.3390/ijms22052354 https://doi.org/10.3390/ijms22052354
38. Radenkovic S, Konjevic G, Nikitovic M, et al. Evaluation of Cyclin D1 expression by western blotting methods and immunohistochemistry in breast cancer patients. J BUON. 2021;26(2):475-482.
39. Blanco R, Iwakawa R, Tang M, et al. A gene-alteration profile of human lung cancer cell lines. Hum Mutat. 2009;30(8):1199-1206. https://doi.org/10.1002/humu.21028
40. Kwon JH, Kim KJ, Sung JH, Suh KJ, Lee JY, Kim JW et al. Afatinib overcomes pemetrexed-acquired resistance in non-small cell lung cancer cells harboring an EML4-ALK rearrangement. Cells. 2019 Dec;8(12):1538. https://doi.org/10.3390/cells8121538
41. Baidyuk, E., Shuvalov, O., Daks, A et al. Nucleolar localization of EGFR with different status in lung adenocarcinoma cells. Biopolymers and Cell 2019; 35(3), 200-200. http://dx.doi.org/10.7124/bc.0009D1
42. Todosijević J, Luković J, Obradović J, Jurišić V. Basic research of lung cancer in-vitro: measurement methods, new possibilities and perspective. Rap conference proceedings, 5, 44–50, 2020. https://doi.org/10.37392/RapProc.2020.11
43. Greve G, Schiffmann I, Pfeifer D, Pantic M, Schüler J, Lübbert M. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer. 2015;15:947. Published 2015 Dec 16. https://doi.org/10.1186/s12885-015-1967-5
44. Cheng CC, Chou KF, Wu CW, et al. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. Lung Cancer. 2018;116:80-89. https://doi.org/10.1016/j.lungcan.2017.12.017
45. Herreros-Pomares A, Zhou X, Calabuig-Fariñas S, et al. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study. Mater Sci Eng C Mater Biol Appl. 2021;122:111914. https://doi.org/10.1016/j.msec.2021.111914
46. Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10(1):3991. Published 2019 Sep 5. https://doi.org/10.1038/s41467-019-11867-6
47. Shi R, Radulovich N, Ng C, et al. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26(5):1162-1174. https://doi.org/10.1158/1078-0432.CCR-19-1376
48. Naoki K, Soejima K, Okamoto H, et al. The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. Int J Clin Oncol. 2011;16(4):335-344. https://doi.org/10.1007/s10147-011-0187-5
49. Forcella M, Oldani M, Epistolio S, et al. Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3. PLoS One. 2017;12(10):e0187289. Published 2017 Oct 31. https://doi.org/10.1371/journal.pone.0187289
50. Jiang XW, Liu W, Zhu XY, Xu XX. Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays. Mol Med Rep. 2019;20(1):593-603. https://doi.org/10.3892/mmr.2019.10259
51. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
52. Lam DC, Liam CK, Andarini S, et al. Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023;18(10):1303-1322. https://doi.org/10.1016/j.jtho.2023.06.014
53. Jurišić V, Obradovic J, Pavlović S, Djordjevic N. Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Anal Cell Pathol (Amst). 2018;2018:6192187. Published 2018 Oct 14. https://doi.org/10.1155/2018/6192187
54. Nowacka M, Sterzynska K, Andrzejewska M, Nowicki M, Januchowski R. Drug resistance evaluation in novel 3D in vitro model. Biomed Pharmacother. 2021;138:111536. https://doi.org/10.1016/j.biopha.2021.111536
55. Obradović J, Djordjević N, Tošic N, et al. Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. Tumour Biol. 2016;37(8):10479-10486. https://doi.org/10.1007/s13277-016-4930-4
56. Lichota A, Gwozdzinski K. Anticancer Activity of Natural Compounds from Plant and Marine Environment. Int J Mol Sci. 2018;19(11):3533. Published 2018 Nov 9. https://doi.org/10.3390/ijms19113533
57. Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjević N. EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. J Oncol. 2020 Mar 18;2020:1973241. https://doi.org/10.1155/2020/1973241
2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1 Suppl):21S-49S. https://doi.org/10.1378/chest.123.1_suppl.21s
3. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5-8. https://doi.org/10.1164/ajrccm.161.1.9906062
4. Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45(1):103-110. https://doi.org/10.1086/518606
5. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17(3):362-387. https://doi.org/10.1016/j.jtho.2021.11.003
6. Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937-970. https://doi.org/10.1002/cac2.12359
7. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-1260. https://doi.org/10.1097/JTO.0000000000000630
8. Yatabe Y. Molecular pathology of non-small cell carcinoma. Histopathology. 2024;84(1):50-66. https://doi.org/10.1111/his.15080
9. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7(10):2958-2970.
10. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37 Suppl 4:S9-S15. https://doi.org/10.1016/s0959-8049(01)00231-3
11. Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35(4):575-588. https://doi.org/10.1007/s10555-016-9649-6
12. Verusingam ND, Chen YC, Lin HF, et al. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. J Chin Med Assoc. 2021;84(3):248-254. https://doi.org/10.1097/jcma.0000000000000438
13. Provenzano M, Mocellin S. Complementary techniques: validation of gene expression data by quantitative real time PCR. Adv Exp Med Biol. 2007;593:66-73. https://doi.org/10.1007/978-0-387-39978-2_7
14. Shen J, Behrens C, Wistuba II, et al. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006;66(23):11194-11206. https://doi.org/10.1158/0008-5472.CAN-04-1444
15. Liu J, Lee W, Jiang Z, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012;22(12):2315-2327. https://doi.org/10.1101/gr.140988.112
16. Okada S, Kobayashi S, Inaba H, et al. Flow cytometric DNA analysis of lung cancer cell lines. Tohoku J Exp Med. 1992;168(2):307-310. https://doi.org/10.1620/tjem.168.307
17. Neuperger P, Puskás GL, Szebeni JG. A humán H1975 tüdő- és MDA-MB-231 emlőadenokarcinóma-sejtes modellek egysejt-tömegcitometriás összehasonlító elemzése [Single cell mass cytometric comparison of human H1975 lung and MDA-MD-231 breast adenocarcinoma cellular models]. Magy Onkol. 2021;65(2):129-138.
18. Sakamoto Y, Xu L, Seki M, et al. Long-read sequencing for non-small-cell lung cancer genomes. Genome Res. 2020;30(9):1243-1257. https://doi.org/10.1101/gr.261941.120.
19. Mirabelli P, Coppola L, Salvatore M. Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers (Basel). 2019;11(8):1098. Published 2019 Aug 1. https://doi.org/10.3390/cancers11081098
20. Hynds RE, Frese KK, Pearce DR, Grönroos E, Dive C, Swanton C. Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biol. 2021;11(1):200247. https://doi.org/10.1098/rsob.200247
21. Tsai JR, Wang HM, Liu PL, et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell Oncol (Dordr). 2012;35(6):461-471. https://doi.org/10.1007/s13402-012-0105-5
22. Guernet A, Mungamuri SK, Cartier D, et al. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. Mol Cell. 2016;63(3):526-538. https://doi.org/10.1016/j.molcel.2016.06.017
23. Chang TH, Tsai MF, Su KY, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011;183(8):1071-1079. https://doi.org/10.1164/rccm.201009-1440OC
24. Obradovic J, Todosijevic J, Jurisic V. Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Mol Biol Rep. 2021;48(4):3593-3604. https://doi.org/10.1007/s11033-021-06379-w
25. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases [published correction appears in Nat Rev Cancer. 2015 Apr;15(4):247]. Nat Rev Cancer. 2014;14(8):535-546. https://doi.org/10.1038/nrc3775
26. Yablonskii, P., Nefedov, A., Arseniev, A., Kozak, A., Mortada, M., & Patsyuk, A. Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability? AME Medical Journal 5 (2020): 10-10. https://doi:10.21037/amj.2020.02.07
27. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637-658. https://doi.org/10.1038/nrc.2017.84
28. Padinharayil H, Varghese J, John MC, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 2022;10(3):960-989. Published 2022 Aug 23. https://doi.org/10.1016/j.gendis.2022.07.023
29. Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1(1):5-13. https://doi.org/10.3978/j.issn.2218-6751.2011.12.01
30. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019;94(8):1623-1640. https://doi.org/10.3978/j.issn.2218-6751.2011.12.01
31. Zhang Q, Li D, Liu Y, et al. Potential anticancer activity of curcumin analogs containing sulfone on human cancer cells. Archives of Biological Sciences. 2016;68(1):125-133. Accessed January 25, 2024. https://doiserbia.nb.rs/Article.aspx?id=0354-46641500134Z
32. Turkez, H., Arslan, M. E., & Ozdemir, O. Genotoxicity testing: progress and prospects for the next decade. Expert Opin Drug Metab Toxicol. 2017;1089–1098. https://doi.org/10.1080/17425255.2017.1375097
33. Jurisic V, Bogdanovic G, Kojic V, Jakimov D, Srdic T. Effect of TNF-alpha on Raji cells at different cellular levels estimated by various methods. Ann Hematol. 2006;85(2):86-94. https://doi.org/10.1007/s00277-005-0010-3
34. Vuletic A, Konjevic G, Milanovic D, Ruzdijic S, Jurisic V. Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells. Pathol Oncol Res. 2010;16(3):393-401. https://doi.org/10.1007/s12253-009-9241-2
35. Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M. TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239(3):115-122. https://doi.org/10.1007/s00232-010-9309-7
36. Rice SJ, Liu X, Wang HG, Belani CP. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer. PLoS One. 2019;14(5):e0217657. Published 2019 May 31. https://doi.org/10.1371/journal.pone.0217657
37. Maj E, Maj B, Bobak K, et al. Differential Response of Lung Cancer Cells, with Various Driver Mutations, to Plant Polyphenol Resveratrol and Vitamin D Active Metabolite PRI-2191. Int J Mol Sci. 2021;22(5):2354. Published 2021 Feb 26. doi:10.3390/ijms22052354 https://doi.org/10.3390/ijms22052354
38. Radenkovic S, Konjevic G, Nikitovic M, et al. Evaluation of Cyclin D1 expression by western blotting methods and immunohistochemistry in breast cancer patients. J BUON. 2021;26(2):475-482.
39. Blanco R, Iwakawa R, Tang M, et al. A gene-alteration profile of human lung cancer cell lines. Hum Mutat. 2009;30(8):1199-1206. https://doi.org/10.1002/humu.21028
40. Kwon JH, Kim KJ, Sung JH, Suh KJ, Lee JY, Kim JW et al. Afatinib overcomes pemetrexed-acquired resistance in non-small cell lung cancer cells harboring an EML4-ALK rearrangement. Cells. 2019 Dec;8(12):1538. https://doi.org/10.3390/cells8121538
41. Baidyuk, E., Shuvalov, O., Daks, A et al. Nucleolar localization of EGFR with different status in lung adenocarcinoma cells. Biopolymers and Cell 2019; 35(3), 200-200. http://dx.doi.org/10.7124/bc.0009D1
42. Todosijević J, Luković J, Obradović J, Jurišić V. Basic research of lung cancer in-vitro: measurement methods, new possibilities and perspective. Rap conference proceedings, 5, 44–50, 2020. https://doi.org/10.37392/RapProc.2020.11
43. Greve G, Schiffmann I, Pfeifer D, Pantic M, Schüler J, Lübbert M. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer. 2015;15:947. Published 2015 Dec 16. https://doi.org/10.1186/s12885-015-1967-5
44. Cheng CC, Chou KF, Wu CW, et al. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. Lung Cancer. 2018;116:80-89. https://doi.org/10.1016/j.lungcan.2017.12.017
45. Herreros-Pomares A, Zhou X, Calabuig-Fariñas S, et al. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study. Mater Sci Eng C Mater Biol Appl. 2021;122:111914. https://doi.org/10.1016/j.msec.2021.111914
46. Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10(1):3991. Published 2019 Sep 5. https://doi.org/10.1038/s41467-019-11867-6
47. Shi R, Radulovich N, Ng C, et al. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26(5):1162-1174. https://doi.org/10.1158/1078-0432.CCR-19-1376
48. Naoki K, Soejima K, Okamoto H, et al. The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. Int J Clin Oncol. 2011;16(4):335-344. https://doi.org/10.1007/s10147-011-0187-5
49. Forcella M, Oldani M, Epistolio S, et al. Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3. PLoS One. 2017;12(10):e0187289. Published 2017 Oct 31. https://doi.org/10.1371/journal.pone.0187289
50. Jiang XW, Liu W, Zhu XY, Xu XX. Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays. Mol Med Rep. 2019;20(1):593-603. https://doi.org/10.3892/mmr.2019.10259
51. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
52. Lam DC, Liam CK, Andarini S, et al. Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023;18(10):1303-1322. https://doi.org/10.1016/j.jtho.2023.06.014
53. Jurišić V, Obradovic J, Pavlović S, Djordjevic N. Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Anal Cell Pathol (Amst). 2018;2018:6192187. Published 2018 Oct 14. https://doi.org/10.1155/2018/6192187
54. Nowacka M, Sterzynska K, Andrzejewska M, Nowicki M, Januchowski R. Drug resistance evaluation in novel 3D in vitro model. Biomed Pharmacother. 2021;138:111536. https://doi.org/10.1016/j.biopha.2021.111536
55. Obradović J, Djordjević N, Tošic N, et al. Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. Tumour Biol. 2016;37(8):10479-10486. https://doi.org/10.1007/s13277-016-4930-4
56. Lichota A, Gwozdzinski K. Anticancer Activity of Natural Compounds from Plant and Marine Environment. Int J Mol Sci. 2018;19(11):3533. Published 2018 Nov 9. https://doi.org/10.3390/ijms19113533
57. Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjević N. EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. J Oncol. 2020 Mar 18;2020:1973241. https://doi.org/10.1155/2020/1973241
Objavljeno
2025/11/20
Broj časopisa
Rubrika
Pregledni rad / Review article